FEATURES
By Jonathan Bor and Jonathan Bor,Sun Reporter | June 26, 2008
A popular blood-pressure medication has shown promise as a therapy for Marfan syndrome, slowing and, in some cases, stopping the enlargement of a major blood vessel that can lead to fatal ruptures, Johns Hopkins researchers reported today. Although they cautioned that their study was small and the results preliminary, the scientists at Hopkins' School of Medicine say the drug could reduce the need for the open-heart operations that many patients need to stay alive. "The results are telling me that there is the potential to prevent aortic disease for a lifetime," said Dr. Harry Dietz, the Hopkins geneticist and cardiologist who led the study appearing in today's New England Journal of Medicine.
NEWS
By Dennis O'Brien and Dennis O'Brien,Sun reporter | April 21, 2008
A genetic variation common in African-Americans naturally protects heart failure patients as effectively as popular heart medications, researchers reported today. Scientists at the University of Maryland and other institutions tracked more than 300 heart failure patients for up to eight years and found that variations of a particular gene extended the lives of many of them for several years - just as if they were on beta blockers. Researchers found the variation in 40 percent of blacks but only 2 percent of Caucasians.
NEWS
By DENNIS O'BRIEN and DENNIS O'BRIEN,SUN REPORTER | July 11, 2006
Researchers at the University of Maryland School of Medicine say they have solved a mystery that has intrigued cardiologists for years: why one of the most commonly prescribed heart medications doesn't always work. The effectiveness of beta blockers - a class of drugs given to many of the estimated 5 million patients with chronic heart failure - depends on the genetic makeup of receptors in the heart, said Dr. Stephen B. Liggett, head of the school's cardiopulmonary genomics program and lead author of the beta blockers study.
NEWS
By Joe Graedon and Teresa Graedon and Joe Graedon and Teresa Graedon,King Features Syndicate | June 26, 2005
I've read about a pill to combat "stage fright" symptoms in public speaking or similar situations. It is called "propol-something" and is taken before the event. Do you know what it is and if it works? You are probably referring to a medication called propranolol (Inderal). This beta blocker is prescribed for problems from high blood pressure and irregular heart rhythms to angina and migraine prevention. Propranolol and other beta blockers are used clandestinely by many musicians to control stage fright, but the Food and Drug Administration has never approved these drugs for this purpose.
NEWS
By Thomas M. Maugh and Thomas M. Maugh,LOS ANGELES TIMES | November 19, 2004
Heart disease is the bane of diabetics. Fully 80 percent of diabetics die of cardiovascular disease, and efforts to lower the risk by reducing blood pressure, lowering cholesterol and eliminating other risk factors have had minimal success. About 7 percent of diabetics are able to bring cardiac risk factors to desired levels. One big problem is that drugs that lower blood pressure can be counterproductive, exacerbating diabetes as they reduce hypertension. The key class of drugs known as beta blockers, for example, has repeatedly been demonstrated to be more effective at lowering blood pressure in diabetics than in those without the disease.
NEWS
By Jane E. Allen and By Jane E. Allen,Special to the Sun | August 4, 2002
A class of highly effective heart drugs called beta-blockers have developed a reputation for causing depression, impotence and fatigue. But a new study has found that the drugs' reputed side effects have been overblown. The study of 15 trials involving 35,000 patients was conducted by researchers trying to understand why so many physicians are reluctant to prescribe beta-blockers, even though they lower blood pressure, improve heart function and survival in patients with heart failure, and reduce deaths after heart attacks by 20 percent.